CStone Pharmaceuticals Valuation
Is 2616 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2616 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2616's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2616's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2616?
Other financial metrics that can be useful for relative valuation.
| What is 2616's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥1.06b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | -0.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 2616's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.9x | ||
1061 Essex Bio-Technology | 0.7x | n/a | HK$1.2b |
1672 Ascletis Pharma | 22.2x | -19.0% | HK$1.4b |
2137 Brii Biosciences | 14x | 65.4% | HK$846.4m |
2487 Cutia Therapeutics | 14.8x | 39.2% | HK$2.2b |
2616 CStone Pharmaceuticals | 2.3x | 27.2% | HK$1.1b |
Price-To-Sales vs Peers: 2616 is good value based on its Price-To-Sales Ratio (2.3x) compared to the peer average (12.9x).
Price to Earnings Ratio vs Industry
How does 2616's PE Ratio compare vs other companies in the HK Biotechs Industry?
Price-To-Sales vs Industry: 2616 is good value based on its Price-To-Sales Ratio (2.3x) compared to the Hong Kong Biotechs industry average (12.1x).
Price to Sales Ratio vs Fair Ratio
What is 2616's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.3x |
| Fair PS Ratio | 3.6x |
Price-To-Sales vs Fair Ratio: 2616 is good value based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (3.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | HK$0.90 | HK$3.45 +283.2% | 15.3% | HK$3.98 | HK$2.92 | n/a | 2 |
| Apr ’25 | HK$0.94 | HK$3.64 +286.9% | 10.0% | HK$4.00 | HK$3.27 | n/a | 2 |
| Mar ’25 | HK$1.48 | HK$3.66 +147.6% | 10.7% | HK$4.06 | HK$3.27 | n/a | 2 |
| Feb ’25 | HK$1.60 | HK$4.93 +208.4% | 36.4% | HK$7.44 | HK$3.29 | n/a | 3 |
| Jan ’25 | HK$2.27 | HK$5.45 +140.2% | 26.7% | HK$7.47 | HK$4.10 | n/a | 3 |
| Dec ’24 | HK$2.22 | HK$5.36 +141.2% | 26.2% | HK$7.29 | HK$4.00 | n/a | 3 |
| Nov ’24 | HK$2.12 | HK$5.32 +151.0% | 26.8% | HK$7.28 | HK$3.91 | n/a | 3 |
| Oct ’24 | HK$1.85 | HK$4.99 +170.0% | 27.5% | HK$7.30 | HK$3.93 | n/a | 4 |
| Sep ’24 | HK$2.23 | HK$4.99 +124.0% | 27.5% | HK$7.30 | HK$3.93 | n/a | 4 |
| Aug ’24 | HK$2.50 | HK$6.27 +151.0% | 51.6% | HK$11.82 | HK$4.00 | n/a | 4 |
| Jul ’24 | HK$2.49 | HK$6.96 +179.6% | 42.9% | HK$11.79 | HK$4.03 | n/a | 4 |
| Jun ’24 | HK$2.80 | HK$7.27 +159.7% | 43.3% | HK$12.44 | HK$4.25 | n/a | 4 |
| May ’24 | HK$3.32 | HK$7.27 +119.0% | 43.3% | HK$12.44 | HK$4.25 | n/a | 4 |
| Apr ’24 | HK$3.55 | HK$7.27 +104.8% | 43.3% | HK$12.44 | HK$4.25 | HK$0.94 | 4 |
| Mar ’24 | HK$4.11 | HK$8.14 +98.1% | 35.6% | HK$12.12 | HK$5.30 | HK$1.48 | 3 |
| Feb ’24 | HK$5.09 | HK$8.37 +64.5% | 33.6% | HK$12.28 | HK$5.78 | HK$1.60 | 3 |
| Jan ’24 | HK$4.63 | HK$8.37 +80.9% | 33.6% | HK$12.28 | HK$5.78 | HK$2.27 | 3 |
| Dec ’23 | HK$3.53 | HK$8.37 +137.2% | 33.6% | HK$12.28 | HK$5.78 | HK$2.22 | 3 |
| Nov ’23 | HK$3.49 | HK$8.17 +134.2% | 35.0% | HK$12.20 | HK$5.78 | HK$2.12 | 3 |
| Oct ’23 | HK$3.50 | HK$8.17 +133.5% | 35.0% | HK$12.20 | HK$5.78 | HK$1.85 | 3 |
| Sep ’23 | HK$4.67 | HK$8.61 +84.5% | 27.2% | HK$11.92 | HK$6.85 | HK$2.23 | 3 |
| Aug ’23 | HK$3.97 | HK$8.86 +123.2% | 26.6% | HK$12.19 | HK$7.00 | HK$2.50 | 3 |
| Jul ’23 | HK$5.25 | HK$8.72 +66.1% | 29.8% | HK$12.34 | HK$6.36 | HK$2.49 | 3 |
| Jun ’23 | HK$5.34 | HK$10.68 +100.0% | 50.4% | HK$18.27 | HK$6.34 | HK$2.80 | 3 |
| May ’23 | n/a | HK$11.47 0% | 47.9% | HK$19.16 | HK$6.65 | HK$3.32 | 3 |
| Apr ’23 | HK$5.04 | HK$11.47 +127.7% | 47.9% | HK$19.16 | HK$6.65 | HK$3.55 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.